Second-Line Pharmacotherapy Intensification After Metformin Monotherapy in Type 2 Diabetes: A Nationwide Register Study From Finland During 2011-2022

Tiivistelmä

Background

In this nationwide register study, we examined the initiation of a second-line antidiabetic medicine (ADM) among new patients receiving regular metformin monotherapy in Finland during 2011-2022. We also reflected the second-line treatment patterns on changes in the reimbursement policy, and the national type 2 diabetes (T2D) care guidelines.

Methods

Using register data on all reimbursed ADM purchases during 2010-2022, we defined nine annual cohorts of patients initiating regular metformin monotherapy during 2011-2019, each with a three-year follow-up. Descriptive methods were used to study the patterns of metformin monotherapy and second-line intensification over time. Proportional hazards models were used to analyse the take-up of the second-line ADM.

Results

The share of new patients initiating metformin use (11-13% of all metformin users) and regular metformin use (83-85% of all new metformin users) remained stable. In all cohorts, 16-19% of the patients took up a second-line ADM (median time to intensification 1.5 years). With the 2011 cohort as reference, the highest proportion of new regular metformin users taking up a second ADM (hazard ratio 1.12. 95% confidence interval 1.07 ; 1.16, P < .0001) was in the 2019 cohort. In the 2017 cohort, the proportion of patients initiating sodium-glucose cotransporter 2 inhibitors as second-line treatment surpassed those initiating dipeptidyl peptidase-4 inhibitors. The reimbursement policy restricted the use of GLP-1-analogues.

Conclusions

Second-line treatment intensification patterns over time paralleled the changes in the reimbursement system. Thus, our findings suggest that the reimbursement policy may influence the use of ADMs in Finland.

Lue koko artikkeli (biomedcentral.com)

Tekijät

Hanna Rättö, Terhi Kurko, Pia Pajunen, Helena Kastarinen

Lisätietoja julkaisusta

• Vertaisarvioitu: kyllä.
• Avoin saatavuus: kyllä.
• Koko viite: Rättö, H., Kurko, T., Pajunen, P., & Kastarinen, H. (2024). Second-line pharmacotherapy intensification after metformin monotherapy in type 2 diabetes: a nationwide register study from Finland during 2011-2022. BMC health services research, 24(1), 944. https://doi.org/10.1186/s12913-024-11325-0